Table 1.
Baseline characteristics
| PCC, N = 595 | PMC, N = 595 | P Value | |
|---|---|---|---|
| Age, y | 58.3 ± 10.0 | 57.9 ±10.9 | 0.480 |
| Male sex | 430 (72.3) | 430 (72.3) | 0.526 |
| HTN | 419 (70.4) | 428 (71.9) | 0.304 |
| Hyperlipidemia | 595 (100) | 595 (100) | 1.00 |
| DM | 152 (25.5) | 151 (25.4) | 0.500 |
| Smoker | 94 (15.8) | 96 (16.1) | 0.468 |
| AF | 6 (1.0) | 4 (<1.0) | 0.376 |
| Treatment for HTN | 392 (65.9) | 302 (50.8) | <0.001 |
| BP controlled | 458 (77) | 459 (77) | 0.500 |
| Initial SBP, mm Hg | 128 (120–140) | 128 (119–138) | 0.772 |
| BMI, kg/m2 | 29 (26–33) | 29.4 (26.3–32.8) | 0.653 |
| CV risk estimates | |||
| Initial FRS | 15.86 (9.11–26.58) | 11.53 (6.73–18.89) | <0.001 |
| High | 238 (40) | 135 (22.7) | <0.001 |
| Intermediate | 184 (31) | 208 (35) | 0.078 |
| Low | 173 (29.1) | 252 (42.4) | <0.001 |
| CACS obtained | 493 (82.9) | 65 (10.9) | <0.001 |
| CACS, AU | 131.56 ± 305.16 | 147.631 ± 420.35 | 0.704 |
| Initial lipid values, mg/dL | |||
| TC | 195 (164–221) | 194 (166–223) | 0.833 |
| LDL‐C | 109 (83–137) | 115 (91–143) | 0.036 |
| TG | 124 (81–191) | 117 (85–169) | 0.211 |
| HDL‐C | 48 (39–63) | 47 (40–57) | 0.575 |
| Non–HDL‐C | 140 (113–169) | 144 (117–170) | 0.309 |
| ASA prescription following initial evaluation | |||
| High FRS | 169 | 51 | <0.001 |
| Intermediate FRS | 106 | 64 | <0.001 |
| Low FRS | 62 | 32 | <0.001 |
| Lipid medications | |||
| Low‐intensity statin therapy | 51 (8.6) | 40 (6.7) | 0.275 |
| Moderate‐intensity statin therapy | 176 (29.6) | 169 (28.4) | 0.708 |
| High‐intensity statin therapy | 85 (14.3) | 59 (9.9) | 0.013 |
| Nonstatin lipid therapy only | 85 (14.3) | 33 (5.5) | <0.001 |
| No lipid therapy | 198 (33.2) | 294 (49.4) | <0.001 |
| Combination lipid therapya | 94 (15.8) | 24 (4.0) | <0.001 |
| Initial BP values/treatment | |||
| Treatment for HTN | 392 (65.9) | 302 (50.8) | <0.001 |
| SBP, mm Hg | 130 ± 16 | 129 ± 14 | 0.060 |
| Initial SBP well controlled | 458 (77.0) | 459 (77.1) | 1.000 |
Abbreviations: AF, atrial fibrillation; ASA, acetylsalicylic acid (aspirin); AU, Agatston units; BMI, body mass index; BP, blood pressure; CACS, coronary artery calcium score; CV, cardiovascular; DM, diabetes mellitus; FRS, Framingham Risk Score; HDL‐C, high‐density lipoprotein cholesterol; HTN, hypertension; IQR, interquartile range; LDL‐C, low‐density lipoprotein cholesterol; PCC, preventive cardiology clinic; PMC, propensity‐matched cohort; SBP, systolic blood pressure; SD, standard deviation; TC, total cholesterol; TG, triglycerides.
Data are presented as n (%), mean ± SD, or median (IQR).
a
Statin and nonstatin medication use.